In order to prescribe and/or dispense Aranesp to patients with cancer and anemia due to myelosuppressive chemotherapy, prescribers and hospitals must enroll in
These highlights do not include all the information needed to use ARANESP safely and effectively. See full prescribing information for ARANESP. ARANESP (darbepoetin alfa) i njection, for intravenous or subcutaneous use Initial U.S. Approval: 2024
Clinical Policy: Darbepoetin Alfa (Aranesp). Reference Number: IL.ERX Aranesp Prescribing Information. Thousand Oaks, CA: Amgen Inc
See full prescribing information for ARANESP. ARANESP (darbepoetin alfa ) i njection, for intravenous or subcutaneous use Initial U.S. Approval: 2024 WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
ARANESP 150 ?G; ARANESP 20 ?G; ARANESP 30 ?G; ARANESP 300 ?G; ARANESP 40 ?G CLAZEN XL 500MG; CLENIDERM; CLENIL FORTE; CLEREGIL AD; CLEREGIL ENF; CLIACIL
EC Agrees to Amended Aranesp Prescribing Information Stipulating a uniform target hemoglobin range of 10–12 grams per deciliter; Providing
Patients should be informed of the possible side effects of Aranesp and be instructed to report them to the prescribing physician. caregivers, including
EU Commission Approves Updated Prescribing Information for Aranesp(R) THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Ma-Amgen (NASDAQ: AMGN) today announced that the European Commission reached its final decision to amend the prescribing information for Aranesp(R) (darbepoetin alfa) based on the positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) in
The FDA has released the REMS requirements for the ESA products, Epogen/Procrit and Aranesp, and the risks can be communicated by the current product prescribing information.
Comments
SHOULD BE:
Andy had literally simply RELAYED all the various information.